Search clinical trials for: DACP MF

Total 566 results

Ruijin Hospital

Recruiting

Mutant p53-based Personalized Trial Using Decitabine and Arsenic Trioxide on AML/MDS (PANDA-T0)

P53 Mutation | Myeloid Malignancy | MDS | Aml

China
Biogen
AbbVie

Completed

Safety and Efficacy Study of Daclizumab High Yield Process (DAC HYP) to Treat Relapsing-Remitting Multiple Sclerosis (SELECT)

Relapsing-Remitting Multiple Sclerosis

Czech Republic, Poland, Russian Federation, United Kingdom, Hungary, Ukraine, Germany, India
National Cancer Institute (NCI)

Completed

Bryostatin 1 and Cisplatin in Treating Patients With Metastatic or Unresectable Stomach Cancer

Stage IV Gastric Cancer | Stage III Gastric Cancer

United States
Chinese PLA General Hospital
Navy General Hospital, Beijing

Unknown

Decitabine Followed by Donor Lymphocyte Infusion for Patients With Relapsed Acute Myeloblastic Leukemia(AML) After Allogeneic Stem Cell Transplantation

Recurrent Adult Acute Myeloid Leukemia

China
Novartis Pharmaceuticals

Completed

Safety and Tolerability and Efficacy of LCZ696 in Japanese Severe Hypertensive Patients

Severe Hypertension

Japan
Radiation Therapy Oncology Group
National Cancer Institute (NCI); NRG Oncology

Withdrawn

Radiation Therapy and Cisplatin With or Without Surgery in Treating Patients With Stage III-IV Oropharyngeal Cancer

Tongue Cancer | Stage III Squamous Cell Carcinoma of the Oropharynx | Stage IVA Squamous Cell Carcinoma of the Oropharynx

United States
Ascendis Pharma A/S

Completed

Pharmacokinetics and Pharmacodynamics of ACP-001 (TransCon PEG hGH)

Healthy

Canada
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

Clinical Study of TQB2618 Injection in Combination With Demethylation Drugs in Patients With Recurrent/Refractory Acute Myeloid Leukemia, Myelodysplastic Syndromes

Recurrent/Refractory Acute Myeloid Leukemia, Myelodysplastic Syndromes

China
Acerta Pharma BV

Active, not recruiting

An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma

Mantle Cell Lymphoma (MCL)

Belgium, France, United Kingdom, United States, Italy, Poland, Netherlands, Australia, Czechia, Spain
Acerta Pharma BV

Active, not recruiting

ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia

Chronic Lymphocytic Leukemia | Prolymphocytic Leukemia | Small Lymphocytic Lymphoma | Richter's Syndrome

United States, United Kingdom, Italy
German CLL Study Group

Completed

Efficacy of Acalabrutinib in Very Old or Frail Patients With Treatment-naïve or Relapsed/Refractory CLL (CLL-Frail)

Chronic Lymphoid Leukemia

Austria, Germany
Acerta Pharma BV

Completed

Acalabrutinib (ACP-196), a Btk Inhibitor, for Treatment of de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma

Activated B-cell Diffuse Large B-Cell Lymphoma (ABC DLBCL)

United States, United Kingdom
Biogen
AbbVie

Completed

Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) in Participants With Multiple Sclerosis Who Have Completed Study 205MS201 (NCT00390221) to Treat Relapsing-Remitting Multiple Sclerosis (SELECTION)

Relapsing-Remitting Multiple Sclerosis

Czech Republic, Poland, Russian Federation, United Kingdom, Hungary, Ukraine, Germany, India
National Cancer Institute (NCI)

Completed

Bryostatin 1 and Cisplatin in Treating Patients With Advanced Recurrent or Residual Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

Fallopian Tube Cancer | Stage IV Ovarian Epithelial Cancer | Primary Peritoneal Cavity Cancer | Recurrent Ovarian Epithelial Cancer | Stage III Ovarian Epithelial Cancer

United States
Ain Shams University

Not yet recruiting

Clinical & Radiographic Evaluation of LSTR in Non-vital Primary Molars Using Two Different Vehicles (LSTR)

Resorption of Tooth or Root
Organon and Co
Novartis

Completed

A Patient Handling Study of Mometasone Furoate/Formortoral Fumarate (MF/F) Metered Dose Inhaler (MDI) With an Integrated Dose Counter in Adolescent and Adult Subjects With Asthma or Chronic Obstructive Pulmonary Disease (Study P04703AM1)

Asthma | COPD
Washington University School of Medicine

Completed

Genomic Predictors of Decitabine Response in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute

United States
Waisenmedizin e. V. Promoting Access to Essential...
University of Erlangen-Nürnberg Medical School; German Federal Ministry of... and other collaborators

Completed

Rationales for Wound Care Management in Old World Cutaneous Leishmaniasis Patients (LEICO)

Wound Healing

Afghanistan
UNC Lineberger Comprehensive Cancer Center
AstraZeneca

Active, not recruiting

A Pilot Study of Acalabrutinib in Relapsed/Refractory Primary and Secondary CNS Lymphomas

Central Nervous System Lymphoma

United States
Acerta Pharma BV

Active, not recruiting

A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy

Chronic Lymphocytic Leukemia

United States, United Kingdom, Spain, Israel, France, Belgium
Cairo University

Completed

Remineralization Potential of MI Varnish Versus Fluoride Varnish on White Spot Lesions in Maxillary Primary Incisors

Remineralization Effect of the Varnish on White Spot Lesions

Egypt
AstraZeneca
Parexel

Completed

Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia Patients (ASSURE)

Chronic Lymphocytic Leukemia

United States, France, Italy, Spain, Sweden, Canada, Denmark, Brazil, Taiwan, Australia, Germany, Netherlands, Finland, Norway, United Kingdom, South Korea, Russia
Biogen
AbbVie

Completed

Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) (BIIB019) in Participants Who Have Completed Study 205MS202 (NCT00870740) to Treat Relapsing Remitting Multiple Sclerosis (SELECTED)

Relapsing-Remitting Multiple Sclerosis

Germany, Hungary, Czechia, Russian Federation, India, Poland, Ukraine, United Kingdom
Seema Bhat
AstraZeneca; Acerta Pharma, LLC

Recruiting

Acalabrutinib for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

United States
AstraZeneca
Parexel

Completed

AZD4573 in Novel Combinations With Anti-cancer Agents in Patients With Advanced Blood Cancer

Advanced Haematological Malignancies

Spain, United States, Canada, Korea, Republic of, Poland, Australia, France, United Kingdom, Ireland
University Hospital, Ghent

Completed

A Prospective, Randomized, Clinical Study on the Effects of CPP-ACP-paste, Fluoride and a Combination on the Evolution of White Spot Lesions in Orthodontic Patients After Debonding.

Orthodontic Appliance Complication | White Spot Lesion

Belgium
Innovaderm Research Inc.

Completed

Effect of RANKL Inhibition on UV-induced Immunosuppression

Hypersensitivity, Delayed | Immunosuppression | Ultraviolet Rays | Immune Tolerance/Drug Effects

Canada
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
Acerta Pharma BV

Active, not recruiting

An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström Macroglobulinemia

Waldenström Macroglobulinemia (WM)

France, Spain, United States, United Kingdom, Italy, Greece, Netherlands
Acerta Pharma BV

Active, not recruiting

A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)

Glioblastoma Multiforme

United States
Indiana University
National Institute on Aging (NIA); Regenstrief Institute, Inc.; Hebrew SeniorLife

Completed

Aligning Patient Preferences: a Role Offering Alzheimer's Patients, Caregivers, and Healthcare Providers Education and Support (APPROACHES)

Dementia | Alzheimer Disease

United States
Menarini Group

Completed

Ranolazine in Atrial Fibrillation Following An ELectricaL CardiOversion (RAFFAELLO)

Persistent Atrial Fibrillation

Germany, Italy, Spain, United Kingdom
Fred Hutchinson Cancer Center
AstraZeneca

Recruiting

Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, The AVENUE-2 Trial

Recurrent Small Lymphocytic Lymphoma | Refractory Chronic Lymphocytic Leukemia | Recurrent Chronic Lymphocytic Leukemia | Refractory Small Lymphocytic Lymphoma

United States
Roswell Park Cancer Institute
National Cancer Institute (NCI); Cleveland BioLabs, Inc.

Withdrawn

Entolimod in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer Receiving Cisplatin and Radiation Therapy

Mucositis | Tongue Cancer | Recurrent Squamous Cell Carcinoma of the Hypopharynx | Recurrent Squamous Cell Carcinoma of the Larynx | Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity | Recurrent Squamous Cell Carcinoma of the Oropharynx | Recurrent Squamous Cell Carcinoma of the Paranasal... and other conditions
National Cancer Institute (NCI)

Terminated

Gefitinib and Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III or Stage IV Head and Neck Cancer

Stage III Squamous Cell Carcinoma of the Hypopharynx | Stage III Squamous Cell Carcinoma of the Larynx | Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity | Stage III Squamous Cell Carcinoma of the Oropharynx | Stage IV Squamous Cell Carcinoma of the Hypopharynx | Stage IV Squamous... and other conditions

United States
Emory University
National Cancer Institute (NCI); AstraZeneca

Recruiting

Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas

Mantle Cell Lymphoma | Marginal Zone Lymphoma | Lymphoplasmacytic Lymphoma | Lymphoproliferative Disorder | Indolent Non-Hodgkin Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular Lymphoma

United States
Acerta Pharma BV

Active, not recruiting

Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia

United States, Italy, Spain, United Kingdom, Belgium, Denmark, France, Hungary, Poland, Australia, Germany, Israel, Netherlands, New Zealand, Turkey (Türkiye)
M.D. Anderson Cancer Center
Eisai Inc.

Completed

Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (H-R MDS)

Myelodysplastic Syndrome | Acute Myelogenous Leukemia

United States
The University of Texas Health Science Center at...

Completed

Wound Healing Following Tooth Extraction and Ridge Preservation Using DFDBA Alone in Particulate Fiber Form and in Combination With Xenograft

Wound Heal | Dental Extraction

United States
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Radiation Therapy and Chemotherapy Before and After Surgery in Treating Patients With Esophageal Cancer

Gastric Cancer | Esophageal Cancer

United States
Heath Skinner

Recruiting

Transoral Surgical Resection Followed by De-escalated Adjuvant IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer

Oropharynx Cancer

United States
National Research Centre, Egypt

Completed

Effect of Different Remineralizing Agents on White Spot Lesions Treatment in Children (RCT)

White Spot Lesion of Tooth

Egypt
Ohio State University Comprehensive Cancer Center

Recruiting

Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
Acerta Pharma BV
National Institutes of Health (NIH)

Completed

Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
Shanghai General Hospital, Shanghai Jiao Tong University...

Recruiting

Demethylating Agents Combined With Venetoclax for High-risk T-cell Lymphoblastic Lymphoma/Leukemia Post-Transplant Relapse Prevention

Relapse | ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION | T-cell Acute Lymphoblastic Leukemia

China
National Center for Tumor Diseases, Heidelberg
AstraZeneca; German Cancer Research Center; PharmaMar

Completed

Study of Olaparib/Trabectedin vs. Doctor's Choice in Solid Tumors (NCT-PMO-1603)

Cancers With DNA Repair-Deficiency

Germany
University of Western Ontario, Canada
Arthrex, Inc.

Unknown

Autologous Conditioned Plasma (ACP) for Patients With Plantar Fasciitis

Chronic Plantar Fasciitis

Canada
Acerta Pharma BV

Completed

A Study to Evaluate the Effect of an Acidic Formulation of Acalabrutinib (ACP-196), Acidic Beverage, or Grapefruit Juice on the Pharmacokinetics (PK) of ACP-196 Alone and Coadministered With Omeprazole

Healthy Volunteers

United States
National Cancer Institute (NCI)

Completed

Sorafenib, Docetaxel, and Cisplatin in Treating Patients With Metastatic or Advanced Gastric or Gastroesophageal Junction Cancer

Metastatic Gastric Cancer | Adenocarcinoma of the Gastroesophageal Junction | Advanced Unresectable Gastric Cancer

United States
The Cleveland Clinic

No longer available

Use Of 3,4-Diaminopyridine (3,4-DAP) In The Treatment Of Lambert Eaton Myasthenic Syndrome (34-DAP)

Lambert-Eaton Myasthenic Syndrome

United States

Search clinical trials for: DACP MF

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bangladesh

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations